Researchers reporting in ACS’ Nano Letters have developed magnesium-based micromotors propelled by hydrogen bubbles, which improved rheumatoid arthritis symptoms when injected into the joints of rats.
Researchers at Washington University School of Medicine in St. Louis have engineered cartilage cells to release an anti-inflammatory drug in response to stresses such cells undergo when they are compressed during weight bearing and movement.
Black Patients with RA Less Likely to Receive a Biologic, More Likely to Be Treated with Glucocorticoids Than Whites
A new study reveals that Black patients with rheumatoid arthritis were less likely to be prescribed a biologic treatment and more likely to use glucocorticoids, which carry a risk of serious long-term side effects. This study highlights ongoing racial disparities in the care of patients with rheumatic disease. Details of the study was shared at ACR Convergence, the American College of Rheumatology’s annual meeting.
New Rheumatoid Arthritis Guideline Emphasizes Maximizing Methotrexate and Biologics, Minimizing Steroids
The American College of Rheumatology (ACR) will preview its 2020 Guideline for the Management of Rheumatoid Arthritis (RA) at ACR Convergence, the ACR’s annual meeting. The comprehensive, clinical recommendations for pharmacologic treatment of RA includes important updates to the previous guideline released in 2015.
“My Disease May Be Invisible, But I’m Not”: Patients Tell Their Stories During Rheumatic Disease Awareness Month
The American College of Rheumatology (ACR) and Simple Tasks™ will recognize the fifth annual Rheumatic Disease Awareness Month (RDAM) this September with an awareness campaign that focuses on amplifying patient voices and experiences.
esearchers at Case Western Reserve University have added to the growing body of understanding about how hydroxychloroquine (HCQ) is not a possible defense against COVID-19.
Specifically, they found that HCQ is not effective in preventing COVID-19 in patients with lupus and rheumatoid arthritis (RA), suggesting a broader interpretation of HCQ as ineffective preventive medicine for the general population. Their findings were recently published in the Annals of the Rheumatic Diseases.
UCLA Health is one of 75 sites around the globe participating in a clinical trial sponsored by the National Institutes of Health to test the effectiveness of a candidate anti-viral drug against COVID-19.
A Rutgers-led team has created better biosensor technology that may help lead to safe stem cell therapies for treating Alzheimer’s and Parkinson’s diseases and other neurological disorders. The technology, which features a unique graphene and gold-based platform and high-tech imaging, monitors the fate of stem cells by detecting genetic material (RNA) involved in turning such cells into brain cells (neurons), according to a study in the journal Nano Letters.
New, late-breaking research discovered that there are significant associations between anti-citrullinated protein bodies (ACPA), a characteristic biomarker for rheumatoid arthritis (RA), and industrial emissions of fine particles matter and sulfur dioxide.